Sign in →

Test ID HPVHR Human Papillomavirus (HPV), High-Risk, DNA In Situ Hybridization


Additional Testing Requirements


If additional interpretation or analysis is needed, request PATHC / Pathology Consultation along with this test.

 

The probe set used in this human papillomavirus (HPV) DNA in situ hybridization (ISH) test cannot detect all potential HPV serotypes that are associated with oropharyngeal squamous cell carcinoma. If this test is negative, a more sensitive test, Human Papillomavirus (HPV) High Risk E6/E7 RNA In Situ Hybridization, could be performed and reported if clinically indicated but will not be billed separately.



Shipping Instructions


Attach the green pathology address label included in the kit to the outside of the transport container.



Necessary Information


A pathology/diagnostic report and a brief history are required.



Specimen Required


Supplies: Pathology Packaging Kit (T554)

Specimen Type: Formalin-fixed, paraffin-embedded tissue block

Specimen Volume: Entire block

 

Specimen Type: Slides

Slides: 5 unstained glass, positively charged slides with 5 (+ or - 1)-microns formalin-fixed, paraffin-embedded tissue


Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)

-Oncology Test Request (T729)

Useful For

Detection of human papillomavirus DNA from high-risk genotypes (16, 18, 31, 33, and 51)

Testing Algorithm

Human papillomavirus (HPV) High Risk E6/E7 RNA ISH could be performed and reported at the discretion of the Mayo pathologist if clinically indicated but will not be billed separately.

Method Name

In Situ Hybridization (ISH)

Reporting Name

HPV High-Risk ONLY DNA ISH

Specimen Type

Special

Specimen Stability Information

Specimen Type Temperature Time Special Container
Special Ambient (preferred)
  Refrigerated 

Clinical Information

Persistent infections with high-risk human papillomavirus (HPV) genotypes (16, 18, 31, 33, and 51) are associated with cervical, vaginal, vulvar, and head and neck malignancies. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) have shown better disease-specific survival and overall survival when compared to HPV-negative cases of OPSCC.

Interpretation

This test, when not accompanied by a pathology consultation request, will be answered as either positive or negative. If additional interpretation or analysis is needed, request PATHC / Pathology Consultation along with this test.

Clinical Reference

1. Belobrov S, Cornall A, Young R, et al: The role of human papillomavirus in p16-positive oral cancers. J Oral Pathol Med. 2018;47(1):18-24

2. Ducatman B: The role of human papillomavirus in oropharyngeal squamous cell carcinoma. Arch Pathol Lab Med. 2018;142(6):715-718

3. Windon M, D'Souza G, Rettig E, et al: Increasing prevalence of human papillomavirus–positive oropharyngeal cancers among older adults. Cancer. 2018;124(14):2993-2999

Day(s) Performed

Monday through Friday

Report Available

5 to 7 days

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88365-Primary

88364-If additional ISH

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HPVHR HPV High-Risk ONLY DNA ISH 49896-4

 

Result ID Test Result Name Result LOINC Value
71194 Interpretation 50595-8
71195 Participated in the Interpretation No LOINC Needed
71196 Report electronically signed by 19139-5
71198 Material Received 81178-6
71593 Disclaimer 62364-5
72111 Case Number 80398-1
Mayo Clinic Laboratories | IHC Catalog Additional Information:

mcl-ish-interp